Assessment of the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis patients: a systematic review and meta-analysis on clinical trials | Renal Replacement Therapy | Full Text

Assessment of the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis patients: a systematic review and meta-analysis on clinical trials | Renal Replacement Therapy | Full Text

Featured article: Assessment of the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis patients: a systematic review and meta-analysis on clinical trials

Residual renal function (RRF) is recognized as a significant factor in improving the prognosis of patients undergoing peritoneal dialysis (PD). Preserving RRF contributes to achieving adequate dialysis targets and improving fluid status.

See this article.